权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Assessment of adult living related liver transplantation utilizing serum anti-liver arginase autoantibody assay : a possible novel strategy prospecting its prognosis.

利用血清抗肝精氨酸酶自身抗体测定评估成人活体相关肝移植：探讨其预后的可能新策略。

基本信息

批准号：
11671141
负责人：
MAFUNE Naoki
金额：
$ 2.05万
依托单位：
Hokkaido University
依托单位国家：
日本
项目类别：
Grant-in-Aid for Scientific Research (C)
财政年份：
1999
资助国家：
日本
起止时间：
1999 至 2000
项目状态：
已结题

项目摘要

Background/Aims : Clinical immuno-biochemical blood test for postoperative recipients of living related liver transplantation (LRLT) is still done by combination of assaying serum liver markers as in the past. Our recent study, determining serum anti-liver arginase autoantibody in patients with liver disease, revealed that the autoantibody titre stayed high in continuous liver distraction but easily decreased after the termination of liver damage. This phenomenon prompted us to seek whether this autoantibody can be utilized as a prognostic marker for a postoperative recipient of LRLT.Based on these findings, we tried to clarify whether the serum AAA shows reasonable change even under the state of immunosupression due to postoperative regimen.Methods : Western blot and ELISA were undertaken for the detection and quantification of the anti-liver arginase autoantibody. In the ELISA system, rat liver arginase was used as a target antigen, taking advantage of its high immunological cross reactivity with human liver arginase and the ease of handling it provides.Results : In the cases with short postopcrative hospitalization (<2 months), AAA levels eventually stayed in "critical zone" settled between 5 and 26 U, including normal range (19.7 ± 6.0U), while in those with poor prognosis with prolonged hospitalization (>6months) or with recurrent short term discharge, AAA was never stayed in that level.Conclusions : AAA can be utilized as a prognostic maker that reflect both liver distraction and immunosupression, which are key factors in LRLT.With this in mind, utilization of AAA might ease clinical testing on recipients.

背景/目标：活体肝移植（LRLT）术后受者的临床免疫生化检测仍沿用以往的血清肝标志物联合检测方法。我们最近对肝病患者血清中抗肝转移酶自身抗体的测定表明，持续性肝转移时自身抗体滴度较高，但在肝损害终止后容易下降。这一现象促使我们寻求这种自身抗体是否可以用作LRLT术后受体的预后标志物。基于这些发现，我们试图澄清血清AAA是否显示出合理的变化，即使在免疫抑制状态下，由于术后region.Methods：Western blot和ELISA进行抗肝磷脂酶自身抗体的检测和定量。在ELISA系统中，利用大鼠肝过氧化物酶与人肝过氧化物酶的高免疫交叉反应性和其提供的易于处理的优点，将其用作靶抗原。在术后住院时间短的病例中（<2个月），AAA水平最终停留在5至26 U之间的“临界区”，包括正常范围（19.7 ± 6.0）U，而预后差、住院时间长者（> 6个月）或复发性短期放电，AAA从未停留在该水平。AAA可以作为反映肝脏牵张和免疫抑制的预后指标，这是LRLT的关键因素。AAA的使用可能会简化对接受者的临床测试。